Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease

Launched by ASSIUT UNIVERSITY · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a type of medication called sodium-glucose cotransporter-2 (SGLT2) inhibitors for treating non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where fat builds up in the liver, which can lead to more serious liver problems. The trial aims to see if these medications can help improve liver health by using special imaging techniques and tissue samples to measure changes in fat and scarring in the liver.

To participate in the trial, individuals need to be over 18 years old, and both men and women can join. However, if someone drinks alcohol regularly, has liver disease from other causes (like hepatitis or autoimmune conditions), or has problems with kidney function, they won't be eligible. The trial is currently not recruiting participants, so it's not yet open for enrollment, but once it starts, participants can expect to undergo tests to see how well the SGLT2 inhibitors work for their liver condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age \>18 years
• • both sex
• Exclusion Criteria:
• • alcohol drinker
• • any cause of liver affection (hepatitis, autoimmune...etc)
• • patients with kidney function affection